Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights PR Newswire - Mon Aug 3, 6:05AM CDT

ROCKVILLE, Md. , Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results...

RGNX : 10.41 (+4.52%)
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm PR Newswire - Tue Jul 21, 6:29PM CDT

NEW YORK , July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) ...

RGNX : 10.41 (+4.52%)
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting PR Newswire - Sat Jul 18, 1:55PM CDT

ROCKVILLE, Md., , July 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314)...

RGNX : 10.41 (+4.52%)
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants PR Newswire - Fri Jul 17, 6:00AM CDT

ROCKVILLE, Md. , July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per...

RGNX : 10.41 (+4.52%)
REGENXBIO Announces Proposed Public Offering of Common Stock PR Newswire - Thu Jul 16, 3:26PM CDT

ROCKVILLE, Md. , July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an...

RGNX : 10.41 (+4.52%)
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone PR Newswire - Mon Jun 29, 6:05AM CDT

ROCKVILLE, Md. , June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene...

RGNX : 10.41 (+4.52%)
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 PR Newswire - Wed Jun 24, 6:05AM CDT

ROCKVILLE, Md. , June 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene...

RGNX : 10.41 (+4.52%)
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II PR Newswire - Mon Jun 22, 6:30AM CDT

ROCKVILLE, Md. , June 22, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has aligned with the U.S. Food and Drug Administration (FDA) regarding the next steps needed for...

RGNX : 10.41 (+4.52%)
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire - Mon May 18, 3:05PM CDT

ROCKVILLE, Md. , May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

RGNX : 10.41 (+4.52%)
RGNX: The Duchenne Data That Could Redefine Everything Investors Thought They Knew Barchart - Fri May 15, 4:02PM CDT

Barchart Research What to Expect from RGNX Earnings RGNX Generated May 15, 2026 Current Price $5.72 EPS Estimate $$0.21 Consensus Rating Strong Buy Average Move 4.28% RGNX: The Duchenne Data That Could...

RGNX : 10.41 (+4.52%)

Barchart Exclusives

This Analyst Just Downgraded eBay Stock. Here's Why. Barchart - 43 minutes ago
Wells Fargo downgrades eBay stock ahead of its quarterly earnings scheduled for Aug. 5. Here’s why analyst Ken Gawrelski sees downside in EBAY shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.